Abstract
Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Current Pharmaceutical Design
Title:Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Volume: 19 Issue: 18
Author(s): Biyin Cao, Jie Li and Xinliang Mao
Affiliation:
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Abstract: Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Export Options
About this article
Cite this article as:
Cao Biyin, Li Jie and Mao Xinliang, Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/ 10.2174/13816128113199990338
DOI https://dx.doi.org/ 10.2174/13816128113199990338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Role of IL-10 in the Resolution of Airway Inflammation
Current Molecular Medicine A Dual Role for Sirtuin 1 in Tumorigenesis
Current Pharmaceutical Design Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Radioprotective Gene Therapy
Current Gene Therapy Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Defective and Excessive Immunities in Pediatric Diseases
Current Pharmaceutical Design Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials Balancing the Double-Edged Sword: Metal Ion Homeostasis and the Ulcer Bug
Current Medicinal Chemistry The Role of Cancer Biomarkers in HIV Infected Hosts
Current Medicinal Chemistry CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design MicroRNA Expression in Coronary Artery Disease
MicroRNA Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Secondary Neoplasms in Children Treated for Cancer
Current Pediatric Reviews Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets